公开(公告)号：US11820778B2

公开(公告)日：2023-11-21

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11485742B2

公开(公告)日：2022-11-01

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US10751417B2

公开(公告)日：2020-08-25

申请号：US15957474

申请日：2018-04-19

Applicant: NOVARTIS AG

Inventor： Christopher M. Adams ,  Myriam April ,  Tanzina Fazal ,  Cornelia Jutta Forster ,  Edward Charles Hall ,  Cameron Chuck-munn Lee

IPC: A61K47/36 ,  A61K47/61 ,  A61K47/69 ,  A61P27/02 ,  A61K9/00 ,  A61K31/496 ,  A61K47/10 ,  A61K47/22

Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

公开(公告)号：US12122761B2

公开(公告)日：2024-10-22

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11548865B2

公开(公告)日：2023-01-10

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20180243297A1

公开(公告)日：2018-08-30

申请号：US15963535

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Benjamin Richard Bellenie ,  Graham Charles Bloomfield ,  Ian Bruce ,  Andrew James Culshaw ,  Edward Charles Hall ,  Gregory John Hollingworth ,  James Neef ,  Matthew Spendiff ,  Simon James Watson

IPC: A61K31/497 ,  C07D413/14 ,  A61K31/5377 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/04 ,  C07D409/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04

CPC classification number: A61K31/497 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.